Nifty
Sensex
:
:
22248.40
73230.27
30.95 (0.14%)
72.03 (0.10%)

Pharmaceuticals & Drugs - Domestic

Rating :
65/99

BSE: 506820 | NSE: ASTRAZEN

5501.20
22-Feb-2024
  • Open
  • High
  • Low
  • Previous Close
  •  5499.80
  •  5533.00
  •  5396.10
  •  5496.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  24022
  •  1319.94
  •  7220.95
  •  3098.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 13,739.75
  • 98.63
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 13,219.50
  • 0.29%
  • 20.48

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 1.58%
  • 17.09%
  • FII
  • DII
  • Others
  • 2.66%
  • 2.75%
  • 0.92%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.78
  • 6.61
  • 7.23

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 18.29
  • 4.04

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.77
  • 2.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 106.93
  • 98.67
  • 96.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.47
  • 18.47
  • 16.70

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 60.17
  • 58.30
  • 57.39

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • AstraZeneca Pharma gets nod to import pharmaceutical formulations of new drug for sale
    20th Jan 2024, 16:59 PM

    The company has received permission from Central Drugs Standard Control Organisation

    Read More
  • AstraZeneca Pharma to launch Trastuzumab deruxtecan in January 2024
    21st Dec 2023, 09:30 AM

    Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen

    Read More
  • AstraZeneca Pharma India gets nod to import pharmaceutical formulations of new drug
    4th Dec 2023, 10:29 AM

    The company has received approval from Central Drugs Standard Control Organisation

    Read More
  • AstraZeneca Pharma gets permission to import pharmaceutical formulations
    22nd Nov 2023, 09:39 AM

    The receipt of this permission paves way for the launch of Olaparib film coated tablets of 100mg/150mg (Lynparza) in India

    Read More
  • AstraZeneca Pharma India planning to exit manufacturing site in Bangalore
    16th Nov 2023, 16:44 PM

    The Company will position the manufacturing site for sale in a fully operational manner

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.